Q1 2025 13F Holders as of 31 Mar 2025
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
66,577,393
-
Total 13F shares
-
32,345,011
-
Share change
-
+3,983,664
-
Total reported value
-
$101,559,895
-
Put/Call ratio
-
26%
-
Price per share
-
$3.14
-
Number of holders
-
116
-
Value change
-
+$10,196,300
-
Number of buys
-
65
-
Number of sells
-
33
Institutional Holders of Cardiff Oncology, Inc. - Common Stock (CRDF) as of Q1 2025
As of 31 Mar 2025,
Cardiff Oncology, Inc. - Common Stock (CRDF) was held by
116 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
32,345,011 shares.
The largest 10 holders included
COMMODORE CAPITAL LP, BlackRock, Inc., VANGUARD GROUP INC, Pfizer Inc, BLAIR WILLIAM & CO/IL, ADAGE CAPITAL PARTNERS GP, L.L.C., ACORN CAPITAL ADVISORS, LLC, GEODE CAPITAL MANAGEMENT, LLC, STATE STREET CORP, and MAI Capital Management.
This page lists
116
institutional shareholders reporting positions in this security
for the Q1 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.